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Abstract: A rapid blood-based diagnostic modality to detect pancreatic ductal adenocarcinoma (PDAC) with high ac-
curacy is an unmet medical need. The study aimed to validate a unique diagnosis system using Probe Electrospray 
Ionization Mass Spectrometry (PESI-MS) and Machine Learning to the diagnosis of PDAC. Peripheral blood samples 
were collected from a total of 322 consecutive PDAC patients and 265 controls with a family history of PDAC. Five µl 
of serum samples were analyzed using PESI-MS system. The mass spectra from each specimen were then fed into 
machine learning algorithms to discriminate between control and cancer cases. A total of 587 serum samples were 
analyzed. The sensitivity of the machine learning algorithm using PESI-MS profiles to identify PDAC is 90.8% with 
specificity of 91.7% (95% CI 83.9%-97.4% and 82.8%-97.7% respectively). Combined PESI-MS profiles with age and 
CA19-9 as predictors, the accuracy for stage 1 or 2 of PDAC is 92.9% and for stage 3 or 4 is 93% (95% CI 86.3-98.2; 
87.9-97.4 respectively). The accuracy and simplicity of the PESI-MS profiles combined with machine learning provide 
an opportunity to detect PDAC at an early stage and must be applicable to the examination of at-risk populations.
Keywords: Probe electrospray ionization mass spectrometry (PESI-MS), pancreatic ductal adenocarcinoma (PDAC), 
machine learning 
Introduction
The outlook for pancreatic ductal adenocarci-
noma (PDAC) remains dismal due to lack of 
diagnostics effective for early detection, which 
leads to the diagnosis at advanced stage. As 
the majority of patients presented with ad- 
vanced disease the 5-year survival rates re- 
main below 10% [1]. To improve the prognosis 
of PDAC will require earlier detection, ideally 
utilising diagnostic technique that could be 
employed in at risk populations such as those 
with diabetes [2]. Currently serum carbohy-
drate antigen 19-9 (CA19-9) is the most widely 
used diagnostic test but, due to false-positivity 
in patients with cirrhosis, chronic pancreatitis, 
cholangitis, other malignancies and false-ne- 
gativity in Lewis blood-type negative patients, 
cannot be recommended for general screen- 
ing [3]. CA19-9 is reported to discriminate 
between PDAC patients and healthy controls or 
benign pancreatic disease with a sensitivity of 
78.2-80.3% and a specificity of 80.2-82.8% [4, 
5]. To improve survival and reduce healthcare 
expenditure, it is estimated that a new diagnos-
tic method will require a minimum sensitivity of 
88% at a specificity of 85% [6].
Advances in cancer diagnosis can be facilitated 
by the parallel development of different tech-
niques which when conflated produce a signifi-
cant improvement in diagnostic accuracy. Both 
mass spectrometry and artificial intelligence 
are now established techniques in the medical 
armamentarium and machine learning, an ap- 
plication of artificial intelligence (AI) that en- 
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dows systems with the ability to automatically 
learn and improve from experience, has over-
come some of the prejudices inherent within 
medicine and is proving capable of solving 
some of the difficulties associated with large 
and complex datasets. Mass spectrometry is 
a powerful technique for the rapid molecular 
diagnosis of cancer and probe electrospray ion-
ization (PESI) analysis uses a very fine low inva-
sive needle to achieve direct mass spectrome-
try. The probe needle directly collects a small 
amount of tissue without pretreatment [7] and 
detects sets of low-molecular-weight metabo-
lites and lipids in specimens which provide im- 
portant information for disease detection. For 
biological samples it is one of the commonly 
used and successful ambient ionization tech-
niques [8, 9]. PESI-MS has been shown to dis-
criminate renal cell carcinoma, hepatocellular 
carcinoma and head and neck squamous cell 
carcinoma from surrounding normal tissue 
[10]. Those results support the premise that 
PESI-MS is a versatile and promising technique 
for the identification of a number of different 
malignancies and when combined with AI as a 
potential screening approach in high risk po- 
pulations. Recent studies from Germany, the 
USA and France demonstrated that AI algo-
rithms perform better than dermatologists at 
detecting skin cancer [11]. We recently demon-
strated the potential of PESI-MS combined wi- 
th partial least squares-logistic regression as 
a diagnostic system in animal studies and 
squamous cell carcinoma [10]. The major at- 
traction of PESI-MS is that it is a simple, rapid 
and inexpensive technique which can be easily 
automated and requires minimal sample prep-
aration [12]. The present study aims to de- 
monstrate that PESI-MS combined with AI can 
diagnose PDCA using human serum samples, 
facilitating early diagnosis in the clinical set-
ting, potentially improving patient outcomes 
and reducing healthcare costs. 
Materials and methods
Study population
Between January 2005 and December 2017 
after obtaining written informed consent and 
before treatment at the National Taiwan Uni- 
versity Hospital (NTUH), peripheral blood sam-
ples were collected from a total of 322 pati- 
ents (age 63.6 ± 13.0, female = 45.3%, male = 
54.7%) with cytological and/or pathological 
confirmation of PDAC. All the patients’ demo-
graphic data, including age, gender, serological 
studies, image studies, survival data, and cli- 
nical presentation were collected. Peripheral 
blood was collected from 265 high risk individ-
uals (HRI) age 46.8 ± 14.8 (female 59.6%, male 
40.4%) with a family history of PDAC, participat-
ing in a pancreatic cancer screening program 
at the NTUH between January 2005 and De- 
cember 2015 [13]. Data from control subjects 
included a detailed family history, a full physical 
examination, blood sampling and magnetic res-
onance imaging (MRI). All of the control sub-
jects were followed up for at least 2 years and 
confirmed free of pancreatic malignancy. Se- 
rum collected from PDAC patients and controls 
was stored at -80°C until PESI-MS analysis. 
The study was reviewed and approved by the 
Institutional Review Board of NTUH (No. 2013- 
01048RIND) and University of Yamanashi (No. 
645). Table 1 shows demographic data of the 
study subjects.
PESI-MS analysis
A PESI-MS system (installation of PESI on a 
single quadrupole mass spectrometer com-
partment of LCMS-2020; Shimadzu, Kyoto, 
Japan) was used in the study. Five µl of se- 
rums were added to 95 µl of 50% ethanol in a 
1.5-ml tube and vortexed for 2 min. Samples 
were centrifuged at 150,000×g for 1 minute, 
and the resultant supernatant collected. Sam- 
ple analysis by PESI-MS was performed as 
described previously [14]. All analyses were 
performed in both positive and negative ion 
modes for each specimen. The mass spectra 
from each specimen was generated using 
LabSolutions software (Ver. 5.82 SP1; Shima- 
dzu). PESI is a discontinuous ionization method 
and differs from other ESI methods. The mea-
surement was performed for 2 minutes with a 
time window of 10 sec that demonstrates a 
stable continuous ionization at maximal inten-
sity (ca.50,000). This window was spread out 
into 10 consecutive sets of spectral data. The 
m/z of our analysis ranges from 10 to 2,000, 
which is divided into 1990 bins, each of which 
corresponds to a unitary mass by taking ac- 
count of the mass spectral accuracy of Shi- 
madzu PESI-MS 2020. Each bin contains in- 
formation on m/z as well as the peak intensity 
and they are used to construct the database.
PESI-MS and machine learning for pancreatic cancer
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Table 1. The demographic data of 322 patiensts with pancreatic ductal 
adenocarcinoma (PDAC) and 265 high risk controls (HRCs)
PDAC (n = 322) HRC (n = 265)
Age (years) 63.675 (24.4-91.7) 46.847 (17.7-88.2)
Gender
    Female 146 (45.3%) 158 (59.6%)
    Male 176 (54.7%) 107 (40.4%)
Body-mass index 22.04 (13.3-42.7) 23.24 (15.6-37.7)
Pancreatic cancer location
    Head (head/neck/uncinate) 150 (46.6%)
    Body 111 (34.5%)
    Tail 61 (18.9%)
Stage
    I 11 (3.4%)
    II 66 (20.5%)
    III 60 (18.6%)
    IV 185 (57.5%)
CA-19-9 4558.46 (0.5-66526.69) 15.21 (0-269.4)
CEA 63.309 (0.1-5783.59) 1.734 (0-9.37)
OS (month) 11.35 (0.07-94.22)
Data processing and machine learning
To demonstrate the suitability of PESI-MS to 
detect significant biochemical differences bet- 
ween PDAC and control subjects, a specialized 
machine learning (ML) algorithm was trained 
and tested on each PESI-MS ion mode dataset. 
The positive ion mode dataset contained 583 
subjects (318 PDAC and 265 controls) and the 
negative ion mode 587 subjects (322 PDAC 
and 265 controls). The first objective of the 
algorithm was to accurately distinguish bet- 
ween cancer and control samples. The candi-
date models were trained and tested using 
1,000 independent repetitions of a bootstrap 
cross-validation process (the average over the 
1,000 independent models is reported). Boot- 
strap is a re-sampling technique that can be 
applied as cross-validation to estimate the per-
formance of a model. The method randomly 
splits the data into training and test sets (see 
appendix for more information). An indepen-
dent and automated ML classification model is 
then trained on the training partition of the 
data and tested on the test partition. This 
whole process including the random splitting 
of the data plus model training and validation, 
is independently repeated 1,000 times. The 
performance of each model is recorded and 
the average classification results over the 
1,000 repetitions is cal-
culated and reported in 
the results tables.
The ML algorithm used 
to build the classifica-
tion model was a sup-
port vector machines 
(SVM) [15] and all algo-
rithms have been im- 
plemented in R Statis- 
tical Package. During 
the model selection ph- 
ase of the data analy-
sis, other ML algori-th- 
ms, such as random 
forest [16], partial lea- 
st squares-discriminant 
analysis (PLS-DA) [17] 
and convolutional neu-
ral networks (CNN) [18] 
have been tested but 
SVM produced the best 
overall performance on 
the datasets available. In particular, the CNN 
models seemed to be overkill for binary classi- 
fication (see results in suplementary appendix 
Figure S1 and Table S1). SVM are supervised 
learning algorithms used for regression analy-
sis and classification. By using different ker-
nels, SVM can easily perform non-linear classi-
fication. SVM results reported here are all 
based on a radial basis kernel as it produced 
the best performance results on the present 
dataset. As the number of subject samples is 
large enough and the data do not present too 
many missing values, the different partitions of 
the data used for analysis have always been 
selected in such a way that there are no sub-
jects with missing values (listwise deletion) 
[19].
For each ion mode data (positive and negative) 
two different types of models were extensively 
trained and tested. The first model type used 
only the PESI-MS peaks as predictors (indepen-
dent variables) to discriminate cancer and con-
trol cases. The objective is to show that the 
information from PESI-MS analysis of peripher-
al blood samples alone can discriminate 
between healthy controls and all 4 stages of 
PDAC at least as well as the tumor marker 
CA19-9. The second used the PESI-MS peaks 
(as model type 1) plus age and CA19-9 values 
PESI-MS and machine learning for pancreatic cancer
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Figure 1. Workflow of the data collection, sample analysis and data analysis processes.
as predictors. The sensitivity, specificity, and 
accuracy of each model to discriminate PDAC 
from controls were calculated. Figure 1 depicts 
the workflow of sample collection, sample anal-
ysis and data analysis processes used in this 
study.
Sample exclusion criteria
Serum samples from all 587 subjects were 
analyzed via PESI-MS in both negative (n = 
587 samples) and positive (n = 583 samples) 
ion modes - 4 samples (spectra) from the posi-
tive ion mode were considered inconsistent 
and excluded from the analysis. When adding 
CA19-9 as predictors for diagnosis, samples 
with missing CA19-9 values were excluded. The 
numbers then become 515 samples in nega-
tive ion mode (i.e., 587 excluding 20 PDAC & 
52 control samples) and 512 samples in po- 
sitive ion mode (i.e., 583 excluding 19 PDAC & 
52 control samples). To form the combined 
positive and negative ion mode data, we only 
considered samples with CA19-9 values re- 
corded in both ion modes (n = 512).
Results
High-performance method for diagnosing 
PDAC
The data analysis based on this cohort shows 
that PESI-MS coupled with SVM classifier iden-
tified over 90% of PDAC cases as well as over 
90% of the non-cancer cases with a 91.7% of 
sensitivity (95% CI 91.6-91.8) and a 90.4% of 
specificity (95% CI 90.2-90.6) respectively 
based only on the mass spectra from PESI-MS 
(Table 2 “spectra only as predictors”, negative 
ion mode). The performance of this diagnostic 
approach exceeds the expectation required 
for novel methods for PDAC screening and rep-
resents a valuable tool for the screening of 
PDAC.
PESI-MS and machine learning for pancreatic cancer
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Table 2. Control vs Cancer: average automated cancer diagnosis classification results obtained over 
1,000 independent models built using bootstrap cross-validation
Ion mode
SPECTRA ONLY AS PREDICTORS SPECTRA + AGE + CA19-9 AS PREDICTORS
Negative Positive Negative Positive
Control 265 265 213 213
Cancer 322 318 302 299
Total 587 583 515 512
CLASSIFICATION Accuracy % (95% C.I.) 91.1 (91, 91.2) 89.1 (89, 89.2) 92.8 (92.7, 92.9) 92.7 (92.6, 92.8)
Sensitivity % (95% C.I.) 91.7 (91.6, 91.8) 91.2 (91, 91.4) 95.1 (95, 95.2) 95.9 (95.8, 96)
Specificity % (95% C.I.) 90.4 (90.2, 90.6) 86.7 (86.4, 87) 89 (88.8, 89.2) 87.3 (87, 87.6)
Figure 2. A. PLS-DA scores plot for the combined data (- and + ion modes). 
Separation between samples from healthy controls and stage I + II and 
stage II + IV of PDAC. The model was based on the PESI-MS spectra only 
as predictors. The numbers between parentheses represent % of variance 
from the data explained by each principal discriminant. The dashed lines 
drawn around the clusters represent 95% CI for the respective cluster. B. 
SVM discrimination results (%) for healthy controls vs individual stages of 
PDAC with 95% CI between parentheses.
In order to improve the accura-
cy, we have added several 
parameters as predictors for 
diagnosis (Table 2). In this mo- 
de, we considered the PESI-MS 
spectra and the factors “age” 
and “CA19-9” level as predic-
tors. Inclusion of these two 
parameters drastically improv- 
ed the sensitivity to 95.1% 
(95% C.I: 95.0-95.2) at the 
cost of a decreased specificity 
to 89% (95% C.I: 88.8-89.2) 
(Table 2). 
Discriminating between the 
controls and different stages 
of PDAC
All the results presented in th- 
is section are based only on 
PESI-MS peaks as predictors 
(age and CA19-9 excluded). We 
tested if our system is also 
able to discern the changes in 
metabolites according to the 
cancer stage. A partial least 
squares-discriminant analysis 
(PLS-DA) algorithm (Figure 2A) 
was employed here to discrimi-
nate between (a) “Control”, (b) 
“Earlier PDAC stages” (stages 
1 + 2) and (c) “Advanced PDAC 
stages” (stages 3 + 4) based 
on PES-MS spectra only as 
predictors. The dashed lines 
drawn around the cluster gr- 
oups represent the 95% confi-
dence interval for the respec-
tive cluster. PLS-DA was used 
because it also computes sc- 
ores vectors that can be used 
PESI-MS and machine learning for pancreatic cancer
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Table 3. A. Prediction Combining Decisions from Negative and Positive Ion Modes: average auto-
mated classification results obtained over 1,000 independent bootstrap cross-validations. B. Cancer 
Stage Prediction Combining Decisions from Negative and Positive Ion Modes: average automated 
classification results obtained over 1,000 independent bootstrap cross-validations
A. COMBINED SPECTRA (Negative + Positive ion modes) ONLY AS PREDICTORS
Control 265
Cancer 318
Total 583
CLASSIFICATION Accuracy % (95% C.I.) 91.2 (86.7, 95.8)
Sensitivity % (95% C.I.) 90.8 (83.9, 97.4)
Specificity % (95% C.I.) 91.7 (82.8, 97.7)
B.
COMBINED SPECTRA (Negative + Positive ion modes) + AGE + CA19-9 AS PREDICTORS
*Control vs Earlier PDAC stages Control vs Advanced PDAC stages
Control 213 213
Cancer 68 231
Total 281 444
CLASSIFICATION Accuracy % (95% C.I.) 92.9 (86.3, 98.2) 93 (87.9, 97.4)
Sensitivity % (95% C.I.) 81.2 (57.6, 95.4) 92.7 (84.2, 100)
Specificity % (95% C.I.) 96.8 (92.5, 100) 93.4 (86.2, 100)
*Cohen’s kappa coefficient for the “Control vs Earlier PDAC stages” model is k = 0.8.
to display a scatter plot of the general clus- 
tering of samples. The model was built using 
the combination of both negative and positive 
ion modes to compensate each other for 
achieving more accurate discrimination. Based 
on the biochemical information captured by 
PESI-MS, the subjects spontaneously grouped 
into control, early and advanced stage PDAC. 
At a glance, the control (black triangles) and 
cancer samples (blue and red circles) seem to 
form two well defined and clearly distinct clus-
ters. The results suggest that PESI-MS is able 
to detect subtle alterations in spectra due to 
progression of PDAC. Comparing the separa-
tion of earlier (blue circles) with advanced (red 
circles) cancer stages, the scatter plot also 
shows two distinct clusters but with a slightly 
higher degree of overlap. This implies that dif-
ferent levels of metabolic changes between 
earlier and advanced cancer stages have also 
been detected by PESI-MS.
SVM was also applied to discriminate between 
healthy control patients and individual stages 
of PDAC (Figure 2B). The results show that, on 
average, 91.4% of the PDAC stage 1 patients 
were identified and that the higher the PDAC 
stage the higher the sensitivity of the model; 
over 92% to 97.6% for stages 2, 3 and 4. Table 
S2 in Supplementary Information shows results 
of SVM models discriminating between control 
and PDAC stages.
Combining information from both mass spec-
trometry ion modes 
As MS ion mode is likely to capture slightly dif-
ferent molecular signatures from samples and 
the data analysis of each dataset presented 
slightly different classification results, a com- 
bination of both datasets should be beneficial 
for an automated cancer diagnostic process. 
Therefore, PESI-MS data from both ion modes 
were combined and a new specialized ML algo-
rithm, based on SVM, was individually trained 
and tested to diagnose PDAC. Table 3A pres-
ents the average classification results obtained 
for the automated cancer diagnosis over 1,000 
independent bootstrap cross-validations. The 
results shown in Table 3A suggest that the 
combination of both ion mode datasets is ben-
eficial and the information gained improves the 
performance of the models. On this combined 
dataset, PESI-MS coupled with SVM detected 
with cancer cases 90.8% of sensitivity and 
91.7% of specificity (95% C.I. 83.9-97.4 and 
82.8-97.7) respectively.
Healthy controls vs cancer stages on the com-
bined mass spectrometry ion modes
Surgical resection is the only potentially cura-
tive treatment for PDAC [20]. Based on the 
TNM cancer staging system developed by the 
American Joint Committee on Cancer, pancre-
atic cancers detected in stages 1 and some-
PESI-MS and machine learning for pancreatic cancer
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times 2 are potentially operable. The results 
in Table 3B show that PESI-MS coupled with 
machine learning distinguished between heal- 
thy controls and subjects with earlier stage of 
PDAC (stages 1 or 2) with sensitivity of 81.2% 
and specificity of 96.8% (95% CI: 57.6-95.4 
and 92.5-100) respectively. Although our me- 
thod does not formally stage the disease, it is 
clearly able to detect differences between ear- 
ly and advanced tumors. The results for the 
discrimination between healthy controls and 
subjects with advanced stage PDAC (stages 3 
or 4) are also reported in Table 3B.
Discussion
In this study we have successfully developed 
a novel screening system for pancreatic can- 
cer by simultaneously attaining high sensitivity 
and specificity that exceeds the criteria required 
for PDAC diagnosis and screening. This was 
realized by combination of unique ionization 
method for mass spectrometry (PESI-MS) and 
machine learning that utilizes all the spectral 
data obtained by PESI-MS. Since our system 
does not extract the conspicuous spectral pe- 
aks from the datasets, judgment of cancer is 
based on the broad collections of spectra even 
if there are dozens of peaks relatively higher 
contributing to the diagnosis. Taking the diag-
nostic accuracy up to 91.2%, this method must 
open a new avenue in the diagnosis of PDAC 
ever attained by other methods. Another impor-
tant point that has to be paraphrased here is 
the inexplicability of exact pathophysiological 
mechanism for drawing a diagnosis. Since this 
method relies on the collections of spectral 
peaks telling us the diagnosis possibly due to 
changes in metabolism, we cannot definitely 
narrow down the molecules responsible for 
explaining the molecular mechanisms underly-
ing the cancer. While another important direc-
tion is to identify the molecules for diagnosis 
the PDAC, the focus of this study is validating 
the performance of new diagnostic technique. 
As machine learning does not necessarily re- 
quire us to annotate the molecules underly- 
ing biologic pathways or modifiable risk factors 
that are associated with PDAC [21]. We can 
employ simple and cost-effective mass spec-
trometer whose resolution is not high enough 
for identifying the molecules.
Data-driven machine learning produces cons- 
istent results if significant “learning” of bio-
chemical changes is achieved by a large co- 
hort of PDAC and healthy controls (N = 587 in 
this study). PDAC has been shown to take up 
to a decade following the initial mutation that 
gives opportunity for earlier diagnosis [22]. 
Furthermore, 2-3 year window is open to detect 
PDAC’s at stage 0 and 1. Although we do not 
register the patients at stage 0 or carcinoma in 
situ in our cohort, this technique should be 
applicable at these stages, considering this 
method can achieve an accuracy of 92.2% for 
the detection of early stages of PDAC includ- 
ing stage 1. Therefore, our system is promising 
in PDAC diagnosis that will revolutionize the 
routine of pancreatic diagnosis. 
Metabolomics, including lipidomics, is a feasi-
ble way to identify metabolites responsible for 
PDAC detection [23]. Mayers and co-workers 
had shown that a metabolic biomarker signa-
ture with 9 plasma metabolites plus CA19-9 
differentiated PDAC from chronic pancreatitis 
with diagnostic accuracy of 90.6% (95% CI 
84.9% to 94.6%) [24]. In this study although 
PESI-MS principally measures metabolites and 
lipids we also identified the top 30 discriminat-
ing factors, in negative and positive modes in 
the supplementary appendix (Figures S2 and 
S3). Those peaks include lipid profiles, phos-
pholipids, sphingolipids and cholesterol sul-
fates that have also been identified in other 
studies [25]. Our system does not deviate from 
molecular prediction method while it focuses 
on the fingerprint of responsible molecules.
The serum samples analyzed by PESI-MS do 
not require any pretreatments such as desalt-
ing, fractionation or enrichment. In addition, 
PESI-MS does not require large amount of 
sample for diagnosis, even sub-picoliters of 
samples are sufficient for analysis. In addition 
to these superior attributes, the advantages 
of our system lie in low invasiveness, robust-
ness and rapidity of measurements, and com-
prehensive resolution of substances in the 
samples. 
There are limitations associated with the stu- 
dy mainly related to its retrospective design. It 
must be acknowledged that given a current 
accuracy of 92.9% there is still potential for fur-
ther improvement of machine learning in PDAC 
diagnosis. Because our study population was 
a unique cohort from Taiwan, in other popula-
tions specific optimization will be required. The 
PESI-MS and machine learning for pancreatic cancer
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new diagnostic technique needs validation in 
several independent prospective world-wide 
cohorts. 
Improving the outcome of PDAC will require a 
method which enables early and accurate diag-
nosis. Although the incidence of pancreatic 
cancer is too low to justify whole population 
screening, the accuracy of 92.9% for earlier 
PDAC stage combined PESI-MS and machine 
learning potentially justifies the evaluation of 
high-risk groups. Inherited pancreatic cancer 
syndromes and familial pancreatic cancer are 
the logical targets but other asymptomatic 
groups could be considered [26, 27]. The most 
obvious of these is new-onset diabetes and a 
study from the Mayo Clinic demonstrated that 
diabetes has a 40% prevalence in PDAC and is 
frequently new-onset [28]. 
In conclusion, AI and machine learning have 
begun to enter the field of cancer diagnostics. 
Our study clearly demonstrates the feasibility 
of developing a diagnostic test with a compre-
hensive metabolite profiling MS platform plus 
machine learning that can detect PDAC with 
greater accuracy than has previously been 
achieved with either conventional tumor mark-
ers or a metabolic signature. There is a need for 
prospective, real-world clinical evaluation of 
the diagnostic approach rather than only retro-
spective assessment of performance. The next 
stage is a large-scale diagnostic accuracy study 
among the at-risk populations where the test is 
intended to be employed.
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Table S1. Results averaged over 1,000 independent 
modles from classification using convolutional neural 
network
Control vs cancer (combined dataset positive + negative data)
Accuracy 81.6%
Sensitivity 86.1%
Specificity 73.3%
Supplementary Information
Bootstrap resampling
Bootstrap is a re-sampling technique that can be applied as cross-validation to estimate the perfor-
mance of a model. The method randomly splits the data into training and test sets. Bootstrap does this 
by randomly selecting, with replacement, N samples from a set containing exactly N samples. All select-
ed samples, including the repetitions, are then used as training set and the non-selected samples 
(never seen by the model) are used as test set (1) effectively having all samples analyzed (N = total 
number of subjects “or PESI-MS spectra” available) in a bag. A single sample is then taken out of the 
bag randomly and its number noted. This sample now forms part of the training data, and the sample is 
placed back into the bag. This random sample picking process is repeated until N samples are in the 
training set. Some samples will be used multiple times, and on average, for each bootstrap partition 
63.2% of all of the samples will be selected for training with the remaining 36.8% used as the test set.
Figure S1. Partial representation of a sub convolutional neural network (the full one is too large to plot) with the best 
classification results obtained using CNN shown in Table S1.
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Table S2. Control vs Cancer Stages: average automated classification results obtained over 1,000 
independent models built using bootstrap cross-validations
Ion mode
SPECTRA ONLY AS PREDICTORS
Control vs Earlier PDAC stages Control vs Advanced PDAC stages
Negative Positive Negative Positive
Control 265 265 265 265
Cancer 77 76 245 242
Total 342 341 510 507
CLASSIFICATION Accuracy % (95% C.I.) 87.1 (86.9, 87.3) 88.1 (87.9, 88.3) 91.3 (91.2, 91.4) 89.4 (89.3, 89.5)
Sensitivity % (95% C.I.) 85.9 (85.5, 86.3) 90.2 (89.8, 90.6) 89.1 (88.9, 89.3) 86.2 (85.9, 86.5)
Specificity % (95% C.I.) 88.5 (88.1, 88.9) 86.2 (85.8, 86.6) 93.4 (93.2, 93.6) 92.5 (92.2, 92.8)
Ion mode
SPECTRA + AGE + CA19-9 AS PREDICTORS
Control vs Earlier PDAC stages Control vs Advanced PDAC stages
Negative Positive Negative Positive
Control 213 213 213 213
Cancer 68 68 234 231
Total 281 281 447 444 
CLASSIFICATION Accuracy % (95% C.I.) 90.9 (90.7, 91.1) 91.6 (91.4, 91.8) 91.2 (91.1, 91.3) 91.9 (91.8, 92.0)
Sensitivity % (95% C.I.) 88 (87.6, 88.4) 89.3 (89.0, 89.6) 90.4 (90.2, 90.6) 93.6 (93.4, 93.8)
Specificity % (95% C.I.) 94 (93.7, 94.3) 94.1 (93.8, 94.4) 92.1 (91.9, 92.3) 90.3 (90.1, 90.5)
Figure S2. Top 30 discriminating factors (PESI-MS peaks plus age and CA19-9) for healthy controls vs PDAC using 
the negative ion mode data.
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Figure S3. Top 30 discriminating factors (PESI-MS peaks plus age and CA19-9) for healthy controls vs PDAC using 
the positive ion mode data.
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